Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
Latest in Cardiology from ACC.org
- GOAL-HF1: Novel Ghrelin Receptor Agonist Safe, Well-Tolerated Among Patients With HFrEFAC01, a novel oral calcium-sensitizing isotope and ghrelin receptor agonist designed to increase myocardial contractility, appeared safe and well-tolerated over a 28-day treatment period in patients with heart failure with reduced ejection fraction (HFrEF), according to results from a phase 1b/2a randomized trial published June 24 in The Lancet.
- ACC Scientific Statement Addresses DOACs in Primary and Secondary Prevention of Thrombotic EventsEven with robust evidence demonstrating their efficacy and safety, direct oral anticoagulants (DOACs) continue to be underused and, at times, inappropriately dosed, particularly in patients at elevated thrombotic risk.
- ACC Scientific Statement Guides Use of Antiplatelet Therapy in Managing ASCVDA new ACC Scientific Statement focused on the management of atherosclerotic cardiovascular disease, aims to help clinicians overcome the perpetual challenge of balancing the risk of ischemia with the risk of bleeding in this patient population.
- Withdrawing vs. Continuing GDMT in Patients With Improved Cardiac Function Post AFib AblationIn patients with atrial fibrillation (AFib) with normal cardiac function and sinus rhythm after catheter ablation, 12% who discontinued guideline-directed medical therapy (GDMT) experienced heart failure (HF) deterioration, while drug-related complications were more likely among patients who continued GDMT...
- ACCEL Lite: Impact Of Ivabradine in Post-COVID POTS: The Recover-Autonomic TrialIn this interview, Thomas F. Deering, MD, FACC and Pam Taub, MD, FACC discuss the Recover-Autonomic Trial.